
Charanjit Aulakh
Examiner (ID: 13766, Phone: (571)272-0678 , Office: P/1625 )
| Most Active Art Unit | 1625 |
| Art Unit(s) | 1625, 1621, 1612, 1203 |
| Total Applications | 3843 |
| Issued Applications | 2897 |
| Pending Applications | 386 |
| Abandoned Applications | 597 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17356763
[patent_doc_number] => 20220017559
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => CYCLIC PEROXIDES AS PRODRUGS FOR SELECTIVE DELIVERY OF AGENTS
[patent_app_type] => utility
[patent_app_number] => 17/237525
[patent_app_country] => US
[patent_app_date] => 2021-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57282
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17237525
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/237525 | CYCLIC PEROXIDES AS PRODRUGS FOR SELECTIVE DELIVERY OF AGENTS | Apr 21, 2021 | Abandoned |
Array
(
[id] => 18405781
[patent_doc_number] => 20230167132
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-01
[patent_title] => FORMS AND COMPOSITIONS OF INHIBITORS OF PLASMA KALLIKREIN
[patent_app_type] => utility
[patent_app_number] => 17/919212
[patent_app_country] => US
[patent_app_date] => 2021-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25893
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -83
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17919212
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/919212 | FORMS AND COMPOSITIONS OF INHIBITORS OF PLASMA KALLIKREIN | Apr 15, 2021 | Pending |
Array
(
[id] => 18365346
[patent_doc_number] => 20230146937
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => KAPPA OPIOD RECEPTOR ANTAGONISTS FOR TREATING PAIN-RELATED SLEEP DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/906541
[patent_app_country] => US
[patent_app_date] => 2021-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8873
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17906541
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/906541 | Kappa opiod receptor antagonists for treating pain-related sleep disorders | Apr 8, 2021 | Issued |
Array
(
[id] => 16977579
[patent_doc_number] => 20210221816
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-22
[patent_title] => ACTIVATING PYRUVATE KINASE R AND MUTANTS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/223783
[patent_app_country] => US
[patent_app_date] => 2021-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3733
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17223783
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/223783 | ACTIVATING PYRUVATE KINASE R AND MUTANTS THEREOF | Apr 5, 2021 | Abandoned |
Array
(
[id] => 18296152
[patent_doc_number] => 20230105838
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => Method of Treating COVID-19
[patent_app_type] => utility
[patent_app_number] => 17/906109
[patent_app_country] => US
[patent_app_date] => 2021-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12404
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17906109
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/906109 | Method of treating COVID-19 | Mar 31, 2021 | Issued |
Array
(
[id] => 18359842
[patent_doc_number] => 20230141433
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => TRICYCLIC PESTICIDAL COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/918135
[patent_app_country] => US
[patent_app_date] => 2021-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35914
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17918135
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/918135 | TRICYCLIC PESTICIDAL COMPOUNDS | Mar 30, 2021 | Abandoned |
Array
(
[id] => 18319246
[patent_doc_number] => 20230117374
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => Suppression of Neuroinflammation and Composition and Method Therefore
[patent_app_type] => utility
[patent_app_number] => 17/915751
[patent_app_country] => US
[patent_app_date] => 2021-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8692
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17915751
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/915751 | Suppression of neuroinflammation and composition and method therefor | Mar 30, 2021 | Issued |
Array
(
[id] => 18374265
[patent_doc_number] => 20230149343
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => CANNABICHROMENE FORMULATION FOR PAIN MANAGEMENT
[patent_app_type] => utility
[patent_app_number] => 17/920643
[patent_app_country] => US
[patent_app_date] => 2021-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15833
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17920643
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/920643 | Cannabichromene formulation for pain management | Mar 30, 2021 | Issued |
Array
(
[id] => 20452988
[patent_doc_number] => 12516038
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-06
[patent_title] => Inhibitors of antigen presentation by HLA-DR
[patent_app_type] => utility
[patent_app_number] => 17/907647
[patent_app_country] => US
[patent_app_date] => 2021-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 81864
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 252
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17907647
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/907647 | Inhibitors of antigen presentation by HLA-DR | Mar 29, 2021 | Issued |
Array
(
[id] => 16990115
[patent_doc_number] => 20210228535
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-29
[patent_title] => SMALL MOLECULES AGAINST CANCER
[patent_app_type] => utility
[patent_app_number] => 17/214993
[patent_app_country] => US
[patent_app_date] => 2021-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41132
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17214993
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/214993 | SMALL MOLECULES AGAINST CANCER | Mar 28, 2021 | Abandoned |
Array
(
[id] => 20402219
[patent_doc_number] => 12492187
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-09
[patent_title] => Factor XI activation inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/914826
[patent_app_country] => US
[patent_app_date] => 2021-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8577
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 183
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17914826
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/914826 | Factor XI activation inhibitors | Mar 25, 2021 | Issued |
Array
(
[id] => 19325968
[patent_doc_number] => 12043633
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-23
[patent_title] => Metal complexes, methods, and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/212209
[patent_app_country] => US
[patent_app_date] => 2021-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 13
[patent_no_of_words] => 9163
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 270
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17212209
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/212209 | Metal complexes, methods, and uses thereof | Mar 24, 2021 | Issued |
Array
(
[id] => 17022265
[patent_doc_number] => 20210246136
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-12
[patent_title] => CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/212210
[patent_app_country] => US
[patent_app_date] => 2021-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 79694
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17212210
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/212210 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as aV integrin inhibitors | Mar 24, 2021 | Issued |
Array
(
[id] => 18859228
[patent_doc_number] => 11856840
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-26
[patent_title] => Emitters based on octahedral metal complexes
[patent_app_type] => utility
[patent_app_number] => 17/212144
[patent_app_country] => US
[patent_app_date] => 2021-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 8
[patent_no_of_words] => 10272
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 566
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17212144
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/212144 | Emitters based on octahedral metal complexes | Mar 24, 2021 | Issued |
Array
(
[id] => 20172960
[patent_doc_number] => 12391692
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-19
[patent_title] => Spiro ring-containing quinazoline compound
[patent_app_type] => utility
[patent_app_number] => 17/799060
[patent_app_country] => US
[patent_app_date] => 2021-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5522
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 314
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17799060
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/799060 | Spiro ring-containing quinazoline compound | Mar 22, 2021 | Issued |
Array
(
[id] => 19387866
[patent_doc_number] => 20240277736
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-22
[patent_title] => USE OF PSILOCYBIN IN THE TREATMENT OF NEUROLOGICAL BRAIN INJURY AND MIGRAINES
[patent_app_type] => utility
[patent_app_number] => 17/919420
[patent_app_country] => US
[patent_app_date] => 2021-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6515
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17919420
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/919420 | USE OF PSILOCYBIN IN THE TREATMENT OF NEUROLOGICAL BRAIN INJURY AND MIGRAINES | Mar 17, 2021 | Abandoned |
Array
(
[id] => 18491506
[patent_doc_number] => 11696911
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-07-11
[patent_title] => Antiviral compounds and method for treating RNA viral infection, particularly COVID-19
[patent_app_type] => utility
[patent_app_number] => 17/205823
[patent_app_country] => US
[patent_app_date] => 2021-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 8
[patent_no_of_words] => 10845
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17205823
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/205823 | Antiviral compounds and method for treating RNA viral infection, particularly COVID-19 | Mar 17, 2021 | Issued |
Array
(
[id] => 16946593
[patent_doc_number] => 20210205284
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-08
[patent_title] => THERAPEUTIC COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/201190
[patent_app_country] => US
[patent_app_date] => 2021-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44506
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -51
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17201190
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/201190 | Therapeutic compounds | Mar 14, 2021 | Issued |
Array
(
[id] => 16932379
[patent_doc_number] => 20210198268
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-01
[patent_title] => PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE
[patent_app_type] => utility
[patent_app_number] => 17/202320
[patent_app_country] => US
[patent_app_date] => 2021-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16661
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17202320
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/202320 | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone | Mar 14, 2021 | Issued |
Array
(
[id] => 18028892
[patent_doc_number] => 11512064
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-29
[patent_title] => Salts of an LSD1 inhibitor and processes for preparing the same
[patent_app_type] => utility
[patent_app_number] => 17/200082
[patent_app_country] => US
[patent_app_date] => 2021-03-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 39
[patent_figures_cnt] => 39
[patent_no_of_words] => 39591
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17200082
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/200082 | Salts of an LSD1 inhibitor and processes for preparing the same | Mar 11, 2021 | Issued |